Saturday 17 October 2026
Export RLAY’s income statement to Excel — free account
Relay Therapeutics, Inc.
RLAY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 95.4%, EPS was flat and free cash flow grew 2.13%, each against the same quarter a year earlier.
16.28
1.02
−5.90%
Follow RLAY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 4 | — | — |
+8 more TTM periods Free account |
| (36.77%) | (40.01%) | (41.12%) | (41.14%) | ||
| (33.72%) | (36.39%) | (37.05%) | (37.20%) | ||
ROIC |
0.00% | (157,022.78%) | (1,508.62%) | (1,812.63%) | |
Return on Tangible Assets |
(32.57%) | (43.29%) | (49.87%) | (50.12%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(1.05) | (1.19) | (1.37) | (1.44) | |
Free Cash Flow |
(212.20) | (213.36) | (235.86) | (248.87) | |
Capital Expenditures |
— | — | (0.41) | (0.41) | |
| Other line items | |||||
Cash ROIC |
(11.78%) | (16.61%) | (21.03%) | (20.67%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,455.31% | 1,406.36% | 1,030.61% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
454.04% | 266.95% | 223.60% | 0.00% | |
Share Based Compensation of Revenue |
438.15% | 292.19% | 246.11% | 0.00% | |
Operating CF/Net income |
0.74 | 0.78 | 0.85 | 0.83 | |
Depreciation/Fixed assets |
(1.34) | 0.83 | 0.53 | 0.14 | |
Capex/Depreciation |
0.00 | 0.00 | (0.45) | (1.28) | |
Revenue per Share |
0.05 | 0.10 | 0.15 | 0.00 | |
Operating CF per Share |
(1.05) | (1.19) | (1.37) | (1.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.00 |
Columns are period end dates